EKF Diagnostics Holdings plc (LON:EKF) Insider Buys £3,630 in Stock

EKF Diagnostics Holdings plc (LON:EKFGet Rating) insider Julian Baines purchased 11,000 shares of the firm’s stock in a transaction that occurred on Monday, June 20th. The stock was purchased at an average price of GBX 33 ($0.40) per share, with a total value of £3,630 ($4,446.35).

Shares of EKF Diagnostics stock opened at GBX 31.70 ($0.39) on Friday. EKF Diagnostics Holdings plc has a 52-week low of GBX 30 ($0.37) and a 52-week high of GBX 95 ($1.16). The company has a 50 day moving average of GBX 35.02 and a 200 day moving average of GBX 51.24. The company has a quick ratio of 2.35, a current ratio of 3.48 and a debt-to-equity ratio of 2.78. The company has a market capitalization of £144.21 million and a P/E ratio of 9.15.

The company also recently declared a dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be paid a GBX 1.20 ($0.01) dividend. The ex-dividend date is Thursday, November 3rd. This represents a yield of 2.35%. This is an increase from EKF Diagnostics’s previous dividend of $1.10. EKF Diagnostics’s payout ratio is currently 0.32%.

About EKF Diagnostics (Get Rating)

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples.

Recommended Stories

Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.